Belfast Trust chairman sacked by health minister
The Department of Health said Mr Nesbitt decided on a change of leadership at the trust, saying he believes a fresh start is required.
The minister and department said they would like to thank Mr Mulgrew for his contribution to the trust and the wider health and social care system.
Mr Mulgrew will leave the post on Friday and the department said the process for filling the chair's post is being initiated as a priority.
In a statement, Belfast Trust's interim chief executive Maureen Edwards said she would like to extend "my sincere thanks to Ciaran for his unwavering support, contribution and commitment during his time as trust chairman".
She said Mr Mulgrew had helped the trust through some challenging times since his appointment.
"In particular, he has shown courage and leadership over the last few months in bringing focus and committing to addressing issues around culture and behaviours in our organisation," she said.
"Ciaran always acknowledges the fantastic work of staff in Belfast Trust and is proud of their many achievements. He is leaving the organisation with our gratitude and best wishes for the future.
"I wish to reassure our staff and the public that we will continue to make tangible improvements across the organisation to benefit staff, patients and service users."
Diane Dodds, the Democratic Unionist Party's (DUP) health spokesperson, said the departure of Mr Mulgrew is a "testament to the sheer scale of crisis within the Belfast Trust".
"There have been a series of scandals over recent months and this reflects that. However, it should be remembered that many of these issues predated the current chair's tenure," Dodds said.
She added: "There is a wider systemic problem within the Belfast Trust that will not be resolved by simply removing one individual.
"However, we will need to hear more detail about what exactly has prompted this decision at this time."
Analysis: BBC News NI health reporter Aileen Moynagh
Belfast Trust has been in the headlines for years - from building delays, overspends, and repairs to more recently the cultural issues in the Royal Victoria Hospital's cardiac surgery unit - issues which resulted in extra oversight measures being put in place at the Trust.
And while many of these pre-date Mr Mulgrew's appointment as chair of the Belfast Trust in April 2023, Thursday's announcement suggests the health minister didn't have confidence in the fallout of what's been happening there.
Now people may ask, why Ciaran Mulgrew?
Well, the chairs of each of the health trusts are ministerial appointments, whereas for example, the chief executives aren't.
So, Mr Mulgrew's position was one the health minister had control over.
Does it happen often?
No, it's extremely rare.
Only one other Trust chair has been removed from their post in Northern Ireland in the past and that was in the northern trust in 2012.
So, this sacking of the Belfast Trust chair perhaps answers some of the questions raised about how the health minister would be holding Belfast Trust to account.
Now, while the department said the process for filling the chair's post is a priority, so too is trust appointment of a permanent chief executive to create some stability at its leadership level.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


TechCrunch
32 minutes ago
- TechCrunch
Tony Robbins' and Peter Diamandis' longevity company Fountain Life raises $18M
Eight years ago, orthopedic surgeon Dr. William Kapp attended a medical conference that changed his professional life. He had gone from a private practice doctor to co-founding a company that built critical care hospitals to then selling that company. It gave him an interest for both sides of healthcare: the medicine and business sides, he told TechCrunch. So he went to the annual conference hosted by famed physician-scientist Dr. Daniel Kraft to learn about new tech that could improve results while lowering costs. Dr. Peter Diamandis, founder and chairman of the XPRIZE Foundation, was on stage that year with Dr. Bob Hariri, a stem-cell pioneer and co-founder of several health techs like genomics company, Human Longevity, Kapp said. They discussed genomics, microbiomics, and new tech that wasn't part of mainstream medicine. Inspired, Kapp went back to his home town of Naples, Florida, and 'started a thing called Longevity Performance Center. The idea was to do early detection and then optimization of people's health,' he said. In March 2020, Diamandis (pictured above) and his buddy Tony Robbins heard of Kapp's center and visited. They had a stem cell startup called Fountain Therapeutics. Conversation soon turned toward a merger, and by October that year, the two companies became Fountain Life. Kapp remained CEO with both Diamandis and Robbins as his co-founders and board members. Today his board also includes Hariri as an adviser; Todd Wanek, CEO of Ashley Furniture Industries, as an investor; and wealthy Indian business mogul B.K. Modi as an investor as well. Techcrunch event Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $600+ before prices rise. Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. San Francisco | REGISTER NOW Fountain Life tells TechCrunch exclusively that it just raised an $18 million series B, led by EOS Ventures, with participation from most of the existing members of the board. Fountain previously raised an $80 million Series A and has raised about $108 million total, Kapp said. Longevity as a subject of serious study by the medical community is a new field. When Kapp (pictured below) first launched his center, 'We didn't know exactly what longevity meant,' he said. But over the last four or five years, much more research has been done. The first principle of longevity, he said, is 'don't die of anything stupid.' Therefore, Fountain Life's centers, of which there are four today, have a heavy focus on prevention screening, looking for illnesses and chronic conditions at their earliest stages when they tend to be asymptomatic. Blood tests and body scans gather data on over 100 biomarkers from liver fat to 'microbiome concentrations,' he said. The second principal is optimization, meaning improving those markers with scientifically validated treatments, he said. And the third principal is 'using the latest regenerative therapies under FDA trials,' to treat illness or achieve optimization. Screening tests may discover, for example, small intestinal bacterial overgrowth (SIBO), which, left untreated, may lead to certain cancers, he said. The solution, if caught early, is to restore microbiome balance with specific, prescribed microbiotics. Dr. William Kapp Image Credits:Fountain Life For Fountain's members, testing is repeated every quarter or so, and patients can track results and ask questions of an AI-powered app called Zori. But it's pricey, Kapp admitted. A full subscription costs $30,000 a year, and $10,000 will cover just the testing process and AI, but not ongoing tests and medical support. Still, Kapp remembers two stories that told him this work was on the right track. The wife of a Robbins fan bought a membership for her husband, and the tests caught early-stage, asymptomatic kidney cancer. The husband is now cancer-free. When global hotelier Sam Nazarian was exploring a partnership with Fountain to put longevity centers in luxury hotels, Nazarian did Fountain's tests and found a brain aneurysm. They successfully treated it, Nazarian has publicly said. Kapp says the new funding will allow the company to open more centers. In addition to Naples; Westchester, New York; Orlando; and Dallas, a center in Houston will open in December. Centers in Los Angeles and Miami are planned for Q2 of 2026. He hopes to solve the affordability issue by working on 'clinic development' where Fountain trains medical facilities on its methodologies. Kapp says that as the tech and expertise become more widely available, this will drive down costs for access. Fountain is not the only doctor-driven longevity testing startup. Famed functional health doctor Mark Hyman has a company called Function Health. It offers a package of about 160 blood tests, with follow-up tests every three to six months, for a $500/year membership (with additional fees for additional blood tests). Its platform similarly analyzes and tracks test results, although it doesn't do full body scans or offer direct access to physicians.


The Verge
an hour ago
- The Verge
Some doctors got worse at detecting cancer after relying on AI
We've heard about upskilling and re-skilling due to AI — but how about de-skilling? A new study published this week found that doctors who frequently use AI to detect cancer in one medical procedure got significantly worse at doing so. The researchers set out to discover whether continuous exposure to AI impacted doctors' behavior when conducting colonoscopy, so they decided to assess 'how endoscopists who regularly used AI performed colonoscopy when AI was not in use.' The answer: Not so hot. The rate was about six percentage points lower. The study was published in The Lancet Gastroenterology & Hepatology journal by medical professionals and researchers in countries including Poland, Norway, Sweden, the U.K., and Japan. It followed doctors at four endoscopy centers in Poland, which were part of a trial program focusing on AI's use in colonoscopy for potential cancer prevention. It raises questions about the use of AI in healthcare, when it helps and when it could hurt. Last week, The Verge reported on a Google healthcare AI model's instance of potentially hallucinating a body part and where medical professionals think the industry will go from from this author will be added to your daily email digest and your homepage feed. See All by Hayden Field Posts from this topic will be added to your daily email digest and your homepage feed. See All AI Posts from this topic will be added to your daily email digest and your homepage feed. See All Health Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Science
Yahoo
2 hours ago
- Yahoo
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enhancing drug accessibility. However, challenges such as low adherence and rural access remain. Key market players include Amgen, Eli Lilly, and Pfizer. Saudi Arabian Osteoporosis Drugs Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Osteoporosis Drugs Market to Reach US$ 308.84 Million by 2033 - 4.33% CAGR Driven by Biologics and Aging Population" report has been added to Saudi Arabia Osteoporosis Drugs Market is expected to reach US$ 308.84 million by 2033 from US$ 210.89 million in 2024, with a CAGR of 4.33% from 2025 to 2033 Due to improved healthcare infrastructure, the Saudi Arabian market for osteoporosis medications is concentrated in urban areas like Riyadh, Jeddah, and Dammam, whereas rural areas have less access to experts, diagnostics, and treatment alternatives. Growing rates of osteoporosis, the quick uptake of biologics, and advantageous healthcare laws in a number of Saudi Arabian nations are the main causes of this expansion. While bisphosphonates continue to dominate in volume due to their cost effectiveness, the biologics segment is anticipated to grow at the quickest rate. Government programs under Vision 2030, which prioritize regional medication production and improved healthcare infrastructure, promote the pharmaceutical industry. Osteoporosis treatments are becoming more accessible and reasonably priced as a result of these initiatives, and both name brand and generic medications are essential in satisfying the rising calcitonin, parathyroid hormone analogs, selective estrogen receptor modulators (SERMs), and monoclonal antibodies are among the available treatments. Newer biologic medicines are steadily gaining traction because of their increased efficacy and better patient outcomes, even if bisphosphonates are still frequently administered. Despite progress, issues like poor drug adherence, low awareness in rural regions, and underdiagnosis still exist. Additionally, comprehensive nationwide screening programs and coordinated post fracture care are lacking. Reducing the long term economic cost of osteoporosis in the nation and improving treatment outcomes could be achieved by addressing these challenges through integrated care models, digital health technologies, and Factors Driving the Saudi Arabia Osteoporosis Drugs Market Growth Saudi Arabia's Aging Population Is GrowingBecause osteoporosis and aging are closely related, Saudi Arabia's aging population is a major factor driving up demand for osteoporosis medications. People are more susceptible to fractures, loss of bone density, and associated problems as they get older, especially those over?60. The need for long term therapeutic treatments as well as preventive measures is growing as a result of this demographic shift. More people are reaching the age range where osteoporosis becomes a major concern due to better healthcare and longer life expectancies. As a result, the incidence of osteoporosis is rising in areas with greater populations of elderly persons. In order to assist the aging population and lessen the health burden associated with fractures, this development emphasizes the urgent need for efficient drugs and healthcare Rates of Screening and DiagnosisEarly osteoporosis identification has increased throughout Saudi Arabia thanks to the availability of sophisticated diagnostic technologies including dual energy X ray absorptiometry (DEXA) and bone mineral density (BMD) scanning. These technologies are now widely used in hospitals and clinics, increasing screening accessibility for high risk populations, especially postmenopausal women. In order to encourage early testing and diagnosis, health authorities are aggressively promoting awareness and screening initiatives. Because of this, more people are being diagnosed with bone loss early on, when treatment can be most successful. The number of patients eligible for osteoporosis treatments has increased dramatically due to the increase in early detection, which has increased demand for pharmacological interventions and made it possible to control the condition more effectively over the long Initiated Medical ProgramsAs a national health issue, osteoporosis is being actively addressed by the Saudi Arabian government. It seeks to lower the frequency of fractures and enhance bone health outcomes through education programs, public health campaigns, and preventative measures. Osteoporosis screening and bone density monitoring are becoming more commonplace in national health programs, and access to therapies is being facilitated by drug reimbursement policies and subsidized treatment options. These programs are promoting earlier medical intervention and increasing treatment adherence. Additionally, by making strategic investments in public health, the government's Vision 2030 push for local pharmaceutical development and a larger healthcare infrastructure is bolstering the availability of osteoporosis medications and promoting long term market in the Saudi Arabia Osteoporosis Drugs Market Low Persistence and Adherence to TreatmentLow patient adherence and persistence with prescribed medication regimens is one of the main issues facing Saudi Arabia's osteoporosis management. A lack of immediate, apparent benefits, worries about long term health repercussions, or worries about adverse effects cause many patients to stop treatment too soon. Non-adherence is also influenced by cultural norms and a lack of knowledge about how osteoporosis progresses. Treatment results are harmed as a result, raising the risk of fractures and associated problems. Long term patient involvement is challenging for healthcare practitioners, particularly when patients need daily or weekly oral medication. Enhancing patient education, providing alternate dosage regimens, and incorporating follow up assistance may all contribute to increased adherence and improved population wide therapeutic Treatment Persistence and AdherencePoor patient perseverance and adherence to prescribed treatment regimens is one of the main issues facing osteoporosis care in Saudi Arabia. Due to worries about side effects, worries about long term health repercussions, or a lack of obvious, immediate advantages, many patients stop treatment too soon. Non-adherence is further exacerbated by cultural attitudes and a lack of knowledge regarding the progressive nature of osteoporosis. Treatment results suffer as a result, and the risk of fractures and associated complications rises. It can be challenging for healthcare professionals to stay in touch with patients over the long term, particularly when they need daily or weekly oral medication. Enhancing follow up assistance, providing alternate dose schedules, and improving patient education may all contribute to increased adherence and improved therapeutic efficacy for the general public. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Amgen Inc. Eli Lilly and Company F. Hoffmann La Roche AG GlaxoSmithKline Plc Merck & Co. Inc. Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Ltd. UCB S.A. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $210.89 Million Forecasted Market Value (USD) by 2033 $308.84 Million Compound Annual Growth Rate 4.3% Regions Covered Saudi Arabia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia Osteoporosis Drugs Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Route of Administration6.3 By States7. Product Type7.1 Bisphosphonates7.2 Calcitonin7.3 Rank Ligand Inhibitor7.4 Parathyroid Hormone Therapy (PTH)7.5 Selective Estrogen Receptor Modulators (SERMs)7.6 Sclerostin Inhibitor7.7 Others8. Route of Administration8.1 Oral8.2 Injectable8.3 Others9. Top States9.1 Dhahran9.2 Riyadh9.3 Khobar9.4 Jeddah9.5 Dammam9.6 Others10. Value Chain Analysis11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Pricing Benchmark Analysis13.1 Amgen Inc.13.2 Eli Lilly and Company13.3 F. Hoffmann-La Roche AG13.4 GlaxoSmithKline Plc13.5 Merck & Co. Inc.13.6 Novartis AG13.7 Pfizer Inc.13.8 Teva Pharmaceutical Industries Ltd.13.9 UCB S.A.14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Osteoporosis Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data